Abstract by Ashley Markham
Chemistry and Biochemistry
Pam Van Ry
Biologic Therapeutic for Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a fibrotic lung condition that affects 100,000 people annually in the United States. Once diagnosed with IPF, the average life expectancy is 2-5 years and there are not effective treatments to prolong this life expectancy. In collaboration with the University of Washington, we studied the efficacy of a possible biologic therapeutic for IPF through several functional measurements in the lungs of mice. Pulmonary fibrosis is induced in mice and treated with the therapeutic every three days. Mice were run weekly on an incline until exhaustion, correlating to the six-minute walk test of IPF patients. HR-CT scans were conducted weekly to monitor lung volume and density. Twenty-one days after initial treatment, the mice underwent a tracheostomy and connected to a FlexiVent, which runs a comprehensive lung mechanics test. Data collected from these endpoints suggests this biologic therapeutic helps recover the loss of function in the lungs and decreases the typical pathophysiological signs of pulmonary fibrosis.